Shionogi & Co., Ltd. · TSE:4507
Shionogi & — Shareholder Meeting (June 2024)
21 slides from Shionogi &'s shareholder meeting presentation, June 2024
Slide 1: 159th Annual General Meeting of Shareholders
159th Annual General Meeting of Shareholders - The 159th Business Report - from April 1, 2023 to March 31, 2024. 1
Slide 2: Current State of the Shionogi Group
Current State of the Shionogi Group 2
Slide 3: Building Innovation Platforms to Shape the Future of Healthcare
2030 Vision Appearance after Vision is realized • Continuously creating innovative products/services, Building Innovation with a well-established and rapidly-growing global business Platforms to Shape the - Expansion of business model - Maintenance of high profit margins and growth after overcoming
Slide 4: STS2030 Revision
Strategy Revised from STS2030:STS2030 Revision A new strategy with a clearer path to the realization of the 2030 Vision STS2030 Revision - Shionogi Transformation Strategy 2030 Revision - STS2030 Previous plan STS Phase1 (’20 -’24) STS Phase2 (’25 - ’30) Achieve 2030 Vision STS2030 Revision as a Haa
Slide 5: Reflections on First Year of STS2030 Revision Phase2
Reflections on First Year of STS2030 Revision Phase2 The KPIs set forth in the STS2030 Revision have shown a promising start in alignment with the objectives of STS Phase2 STS Phase2 STS Phase3 FY2023 (Target) FY2023 (Results) FY2025 FY2030 Revenue 450.0 B yen 435.1 B yen 550.0 B yen 800.0 B yen Ove
Slide 6: Business Operations and Results
Business Operations and Results 6
Slide 7: Financial Results (Consolidated) - Revenue
① Financial Results (Consolidated) - Revenue - Revenue by segment (B yen) Revenue FY2022 FY2023 (B yen) Up 2.0% YoY Prescription drugs 179.7 151.1 25.0** 400 Temporary income 100.0* 426.7 435.1 Excluding 300 temporary income 79.7 126.1 Overseas subsidiaries/ 200 export 42.5 49.9 Contract 100 manufac
Slide 8: Financial Results (Consolidated) - Each Profit
① Financial Results (Consolidated) - Each Profit - We achieved a record-breaking revenue and operating profit last fiscal year, surpassing our previous best performance Profit attributable Operating Profit Profit before tax EBITDA* to owners of parent UP 2.9% YoY Down 10.0% YoY Down 12.4% YoY UP 7.5
Slide 9: Financial Results (Consolidated) - Assets, etc.
① Financial Results (Consolidated) – Assets, etc. - Maintain a stable financial base Progress in efforts to improve corporate value over the medium to long term Items of consolidated statement of financial position (B yen) Y on Y FY2022 FY2023 Change(%) Total assets 1,311.8 1,416.9 8.0% Total equity
Slide 10: Domestic Business
② Domestic Business Excluding temporary factors, an increase in sales of domestic prescription drugs 179.7 B yen ■ Temporary factors 151.1 B yen ※1 Purchase of Xocova by the Japanese government ※1 ※2 :100.0 B yen ※2 Transfer of ADHD drugs:25.0 B yen ■ Sales excluding temporary factors 126.1 B yen (U
Slide 11: Stabilization of Revenue through Multiple Infectious Disease Drug Assets
Stabilization of Revenue through Multiple Infectious Disease Drug Assets Realize stable revenue with two anti-infective drug assets, anti-influenza drug and anti-COVID-19 drugs Change in umber of fixed-point reports of influenza and COVID-19 Either Influenza or COVID-19 40 epidemic continues to a ce
Slide 12: Overseas Business
③ Overseas Business • US and Europe: Maximize the value of Cefiderocol (Fetroja/Fetcroja)* • China: Progress toward building a new business model ◼ Revenue from overseas subsidiaries US Europe China 17.9 B yen (UP 15.9% YoY) 15.4 B yen 13.6 B yen (UP 49.9% YoY) 12.0 B yen 10.6 B yen (Down 11.3% YoY)
Slide 13: Royalties and Dividend Income From ViiV
④ Royalties and Dividend Income From ViiV Royalties and dividend income from the HIV franchise stably increased 235.9 B yen 229.7 B yen Royalty incomes and dividend income from ViiV ※ ■ Royalty income (UP 14.7% YoY) ■ Dividend income(Down 44.6% YoY) (※)1. Due to the timing difference in receiving di
Slide 14: R&D
⑤ R&D Accelerated research and development of growth drivers, progressing almost as planned Disease area Pipeline Indication FY2022 FY2023 Consent for S-268019 COVID-19(Origin strain) Submission approval* S-567123 COVID-19(Universal vaccine) Preclinical Infection S-337395 RSV infections Phase 1 Phas
Slide 15: COVID-19 Treatment: Xocova (Ensitrelvir)
COVID-19 Treatment:Xocova(Ensitrelvir) Obtained standard approval in Japan Each clinical trials • Based on positive results from Phase 3 trial in Japan • PEP trial and Asia - Verify the effectiveness of suppressing the • Accumulated safety information from over 900,000 onset of COVID-19 symptoms in
Slide 16: Manufacture and Supply Chain
⑥ Manufacture and Supply Chain Strengthening production and supply chain for achieving STS2030 Revision is progressing smoothly Contributing to the growth Efforts to achieve stable supply of the SHIONOGI Group • Production of COVID-19 related products • Increasing production of Medicon cough – Handl
Slide 17: Challenges Ahead
Challenges Ahead 17
Slide 18: Key Strengthening Points for FY2024 to Achieve STS2030 Revision
Key Strengthening Points for FY2024 to Achieve STS2030 Revision Accelerate growth and investment further to achieve STS2030 Revision • Expand sales of infectious disease drugs in Japan Top-line growth − Improve the presence of Xocova and Xofluza mainly through our own sales ٠ Growth of overseas busi
Slide 19: Dividend Policy
Dividend Policy 19
Slide 20: Shareholder Return Policy through which Shareholders Can Feel Our Growth
Shareholder Return Policy through which Shareholders Can Feel Our Growth FY2023 is the largest annual dividend increase (+25 yen) and plan to increase dividend for the 12th consecutive year +25 yen 160 170 (Planed) (yen) (Planed) 150 135 108 115 103 85 100 94 82 (Planed) 72 75 62 55 60 46 52 44 50 5
Slide 21: Forward-Looking Statements
Forward-Looking Statements • Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclos